123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 67, Issue 2, 1999, Pages 189-194

  Orimo, S ^a,b   Ozawa, E ^a   Nakade, S ^a   Sugimoto, T ^b   Mizusawa, H ^c  

^a Department of Neurology ^*

^b The Mutualaid Association of Public School Teachers)   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Autonomic function tests; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; (3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; HEART; HUMAN; MIDDLE AGED; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; SCINTISCANNING; ESSENTIAL TREMOR; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART SCINTISCANNING; HEART VENTRICLE TACHYCARDIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RR INTERVAL; SHY DRAGER SYNDROME; SYMPATHETIC NERVE;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; AUTONOMIC NERVOUS SYSTEM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; HEART; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; RADIOPHARMACEUTICALS;

EID: 0032588238     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.67.2.189     Document Type: Article

References (37)

1. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978;3:129-33.
2. Ohama E, Ikuta F. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 1976;34:311-9.
3. Hunters S. The rostral mesencephalon in Parkinson's disease and Alzheimer's disease. Acta Neuropathol 1985;68: 53-8.
4. Oppenheimer DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980;46:393-404.
5. Forno LS. Norville RL. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol 1976;34:183-97.
6. Magalhães M, Wenning GK, Daniel SE, et al. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease: a retrospective comparison. Acta Neurol Scand 1995;91:98-102.
7. van Dijk JG, Haan J, Zwinderman K, et al. Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry 1993;56:1090-5.
8. Koike Y, Takahashi A. Autonomic dysfunction in Parkinson's disease. Eur Neurol 1997;38(suppl 2):8-12.
9. 131I] iodobenzylguanidine. J Nucl Med 1980;21:349-53.
10. 123I-MIBG for assessment of sympathetic nervous system in the heart (multi-center clinical trial). Japanese Journal of Nuclear Medicine 1991;28:129-44.
11. Minardo JD, Tuli MM, Moch BH, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78: 1008-19.
12. Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123 metaiodobenzylguanidine. J Am Coll Cardiol 1989;14:1519-26.
13. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
14. Farget D, Wolf J-E, Vanzetto G, et al. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med 1993;34:57-60.
15. Sisson JC, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625-36.
16. Rabinovitch MA, Rose CP, Schwab AJ, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
17. Merlet P, Valette H, Dubois-Randé J-L, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
18. 123I-metaiodobenzylguanidine. Diabetes 1992;41:1069-75.
19. 123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994;49:81-4.
20. Ido A, Sato N, Hasebe N, et al. Assessment of myocardial sympathetic function in patients with Shy-Drager syndrome using I-123 metaiodobenzylguanidine myocardial scintigraphy. Anton Nerv Syst 1995;32:384-90.
21. Serita T, Irita A, Ueyama C, et al. Autonomic nervous function of the heart in patients with Parkinson's disease. Therapeutic Research 1995;16:60-4.
22. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. Neurol Med 1996;45:221-5.
23. 123I-metaiodobenzylguanidine myocardial scintigraphy in patients with Parkinson's disease. J Clin Exp Med (IGAKU NO AYUMI) 1996; 179:949-50.
24. Sato A, Serita T, Tsujihata M. Total defect of metaiodobenzylguanidine (MIBG) imaging on heart in Parkinson's disease: Assessment of cardiac sympathetic denervation. Jpn J Clin Med 1997;55:202-6.
25. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-7.
26. 123I-MIBG scintigraphy in a case with pure autonomic failure. Clin Neurol 1993;33:784-6.
27. Obayashi K, Ando Y, Tanaka Y, et al. A useful tool for autonomic dysfunction: analysis by radio labelled metaiodobenzyl guanidine (MIBG) in patients with peripheral neuropathy. Auton Nerv Syst 1996;33:88-92.
28. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
29. Webster DD. Critical analysis of the disability in Parkinson's disease. Modern Treatment 1968;5:257-82.
30. Schatz IJ, Bannister SR, Freeman RL, et al. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996;46:1470.
31. 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994;15:317-23.
32. Yokota T, Matsunaga T, Okiyama R, et al. Sympathetic skin response in patients with multiple sclerosis compared with patients with spinal cord transection and normal controls. Brain 1991;114:1381-94.
33. Hirashima F, Yokota T, Hayashi M. Sympathetic skin response in Parkinson's disease. Acta Neurol Scand 1996;93:127-32.
34. Goldstein DS, Holmes C, Cannon III RO, et al. Sympathetic cardioneuropathy in dysautonomias. New Engl J Med 1997;336:696-702.
35. Senard JM, Valet P, Durrieu G, et al. Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension. Eur J Clin Invest 1990;20:613-9.
36. Braune HJ, Korchounov AM, Schipper HI. Autonomic dysfunction in Parkinson's disease assessed by sympathetic skin response: a prospective clinical and neurophysiological trial on 50 patients. Acta Neurol Scand 1997;95:293-7.
37. Kuroiwa Y, Shimada Y, Toyokura Y. Postural hypotension and low R-R interval variability in parkinsonism, spinocerebellar degeneration, and Shy-Drager syndrome. Neurology 1983;33:463-7.